Fingerprint
Dive into the research topics of 'Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs?'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs?
Bente Glintborg*, Rikke Ibsen, Rebecca Elisabeth Qwist Bilbo, Merete Lund Hetland, Jakob Kjellberg
*Corresponding author for this work